

Amendment to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) An adjuvant composition, comprising (A) an ionic polysaccharide and (B) an immunostimulating complex that comprises (i) a saponin and (ii) **cholesterol** ~~sterol~~.
- 2.-3. (Canceled)
4. (Previously presented) The adjuvant composition of claim 1, wherein the ionic polysaccharide is an ionic dextran.
5. (Previously presented) The adjuvant composition of claim 4, wherein the ionic dextran is DEAE-dextran.
6. (Previously presented) The adjuvant composition of claim 1, wherein the immunostimulating complex is a protein-free immunostimulating complex.
7. (Currently amended) The adjuvant composition of claim 1, wherein the immunostimulating complex further comprises a phospholipid, and wherein the saponin is Quil A ~~and wherein the sterol is cholesterol~~.
8. (Previously presented) The adjuvant composition of claim 1 wherein the mass ratio of the ionic polysaccharide to the immunostimulating complex is in the range of 50 to 300.
9. (Previously presented) The adjuvant composition of claim 8, wherein the mass ratio is about 125.

10. (Previously presented) The adjuvant composition of claim 1, comprising about 10 mg of the ionic polysaccharide and about 80 μ g of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.

11. (Previously presented) The adjuvant composition of claim 1, comprising about 100 mg of the ionic polysaccharide and about 800 μ g of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.

12. (Previously presented) The adjuvant composition of claim 1, comprising about 150 mg of the ionic polysaccharide and about 500 μ g of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.

13. (Previously presented) An immunogenic composition comprising an immunogen and the adjuvant composition of claim 1.

14. (Previously presented) The immunogenic composition of claim 13, wherein said immunogen comprises LHRH.

15. (Previously presented) The immunogenic composition of claim 14, wherein said immunogen comprises an LHRH-diphtheria toxoid conjugate.

16. (Previously presented) The immunogenic composition of claim 15, comprising 5-500 μ g of LHRH-diphtheria toxoid conjugate, 5-500 mg of the ionic polysaccharide, and 40-4000 μ g of the immunostimulating complex.

17. (Previously presented) A pharmaceutical composition, comprising (i) the immunogenic composition of claim 13, and (ii) one or more pharmaceutically acceptable carriers.

18. (Previously presented) A method of eliciting an effective immune response in an animal, comprising administering to an animal an effective amount of the immunogenic composition of claim 13.

19. (Canceled)

20. (Previously presented) A composition according to claim 8, wherein the mass ratio of ionic polysaccharide component to immunostimulating complex component is in the range of 100 to 140.

21. (Previously presented) The pharmaceutical composition of claim 17, further comprising a pharmaceutically acceptable diluent.

22. (Previously presented) The method of claim 18, wherein said composition further comprises a pharmaceutically acceptable diluent.